JP2003518501A - 新規なグリコシダーゼ阻害剤および特に糖尿病を治療するためのその薬理学的使用 - Google Patents

新規なグリコシダーゼ阻害剤および特に糖尿病を治療するためのその薬理学的使用

Info

Publication number
JP2003518501A
JP2003518501A JP2001548121A JP2001548121A JP2003518501A JP 2003518501 A JP2003518501 A JP 2003518501A JP 2001548121 A JP2001548121 A JP 2001548121A JP 2001548121 A JP2001548121 A JP 2001548121A JP 2003518501 A JP2003518501 A JP 2003518501A
Authority
JP
Japan
Prior art keywords
polyamine
spermidine
group
glucose
amylase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001548121A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003518501A5 (enExample
Inventor
アガジャリ，ヌシン・バヌ・エレーヌ
ロベール，ザビエル・ギ
アゼール，リシャール・ミシェル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Original Assignee
Centre National de la Recherche Scientifique CNRS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS filed Critical Centre National de la Recherche Scientifique CNRS
Publication of JP2003518501A publication Critical patent/JP2003518501A/ja
Publication of JP2003518501A5 publication Critical patent/JP2003518501A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/131—Amines acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2001548121A 1999-12-23 2000-12-20 新規なグリコシダーゼ阻害剤および特に糖尿病を治療するためのその薬理学的使用 Pending JP2003518501A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9916409A FR2802817B1 (fr) 1999-12-23 1999-12-23 Nouveaux inhibiteurs de glycosidases et leurs applications pharmacologiques, notamment pour traiter le diabete
FR99/16409 1999-12-23
PCT/FR2000/003600 WO2001047528A2 (fr) 1999-12-23 2000-12-20 Nouveaux inhibiteurs de glycosidases et leurs applications pharmacologiques, notamment pour traiter le diabete

Publications (2)

Publication Number Publication Date
JP2003518501A true JP2003518501A (ja) 2003-06-10
JP2003518501A5 JP2003518501A5 (enExample) 2005-12-22

Family

ID=9553772

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001548121A Pending JP2003518501A (ja) 1999-12-23 2000-12-20 新規なグリコシダーゼ阻害剤および特に糖尿病を治療するためのその薬理学的使用

Country Status (7)

Country Link
US (1) US20030143713A1 (enExample)
EP (1) EP1239863A2 (enExample)
JP (1) JP2003518501A (enExample)
AU (1) AU2687301A (enExample)
CA (1) CA2395305A1 (enExample)
FR (1) FR2802817B1 (enExample)
WO (1) WO2001047528A2 (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030013772A1 (en) * 2000-02-23 2003-01-16 Murphy Michael A. Composition, synthesis and therapeutic applications of polyamines
US20050085555A1 (en) * 1997-08-21 2005-04-21 Murphy Michael A. Composition, synthesis and therapeutic applications of polyamines
US7312244B2 (en) 1999-04-30 2007-12-25 Cellgate, Inc. Polyamine analog-amino acid conjugates useful as anticancer agents
IL146126A0 (en) 1999-04-30 2002-07-25 Slil Biomedical Corp Novel polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases
DE60029944T2 (de) * 1999-04-30 2007-04-05 Cellgate, Inc., Redwood City Polyamine und ihre therapeutische verwendung
US20030130356A1 (en) * 2001-10-16 2003-07-10 Slil Biomedical Corporation Oligoamine compounds and derivatives thereof for cancer therapy
JP2004189714A (ja) * 2002-12-09 2004-07-08 Rasanen Tiina-Liisa すい臓炎の治療と予防ならびに肝臓再生機能の誘導のための薬剤
WO2007035703A1 (en) 2005-09-20 2007-03-29 Schering Corporation 1- [ [1- [ (2-amin0-6-methyl-4-pyridinyl) methyl] -4-flu0r0-4-piperidinyl,] carbonyl] -4- [2- (2-pyridinyl) -3h-imidaz0 [4 , 5-b] pyridin-3-yl] piperidine useful as histamine h3 antagonist
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
FR2917971B1 (fr) 2007-06-28 2009-10-23 Engelhard Lyon Soc Par Actions Composition amincissante
US8153611B2 (en) * 2007-06-28 2012-04-10 Basf Beauty Care Solutions France S.A.S. Use of sulfated oligosaccharides as slimming cosmetic ingredients
ES2616291T3 (es) * 2007-06-28 2017-06-12 Basf Beauty Care Solutions France Sas Composición adelgazante
AU2008317057B8 (en) 2007-10-22 2014-02-13 Merck Sharp & Dohme Corp. Bicyclic Heterocycle Derivatives and their use as modulators of the activity of GPR119
AU2009249237A1 (en) 2008-05-19 2009-11-26 Schering Corporation Bicyclic heterocycle derivatives and use thereof as GPR119 modulators
ES2522968T3 (es) 2008-06-04 2014-11-19 Synergy Pharmaceuticals Inc. Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
RU2392933C2 (ru) * 2008-07-18 2010-06-27 Учреждение Российской Академии Медицинских Наук Научно-исследовательский институт экспериментальной медицины Северо-западного отделения РАМН (НИИЭМ СЗО РАМН) Средство, обладающее гиполипидемическими свойствами
EP2318388A2 (en) 2008-07-23 2011-05-11 Schering Corporation Tricyclic spirocycle derivatives and methods of use thereof
JP2012504630A (ja) 2008-10-03 2012-02-23 シェーリング コーポレイション グルカゴン受容体アンタゴニストとしてのスピロイミダゾロン誘導体
AU2009303444A1 (en) 2008-10-16 2010-04-22 Schering Corporation Azine derivatives and methods of use thereof
US20110243940A1 (en) 2008-12-16 2011-10-06 Schering Corporation Bicyclic pyranone derivatives and methods of use thereof
EP2379547A1 (en) 2008-12-16 2011-10-26 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
US20110245267A1 (en) 2008-12-19 2011-10-06 Schering Plough Corporation Piperidine and piperazine derivatives and methods of use thereof
WO2010071819A1 (en) 2008-12-19 2010-06-24 Schering Corporation Bicyclic heterocyclic derivatives and methods of use thereof
CA2747809A1 (en) 2008-12-23 2010-07-01 Joel M. Harris Bicyclic heterocycle derivatives and methods of use thereof
WO2010075269A1 (en) 2008-12-23 2010-07-01 Schering Corporation Pyrimidine derivatives as gpcr modttlators for use in the treatment of obesity and diabetes
WO2010075273A1 (en) 2008-12-23 2010-07-01 Schering Corporation Bicyclic heterocycle derivatives and methods of use thereof
WO2010107768A1 (en) 2009-03-18 2010-09-23 Schering Corporation Bicyclic compounds as inhibitors of diacylglycerol acyltransferase
AR076024A1 (es) 2009-04-03 2011-05-11 Schering Corp Derivados de heterociclos biciclicos puenteados y metodos de uso de los mismos
WO2010114957A1 (en) 2009-04-03 2010-10-07 Schering Corporation Bicyclic piperidine and piperazine derivatives as gpcr modulators for the treatment of obesity, diabetes and other metabolic disorders
WO2010144664A1 (en) 2009-06-12 2010-12-16 Schering Corporation Thiophenes as glucagon receptor antagonists, compositions, and methods for their use
EP2477498A4 (en) 2009-09-14 2013-02-27 Merck Sharp & Dohme INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE
US8759357B2 (en) 2009-10-08 2014-06-24 Merck Sharp & Dohme Corp. Inhibitors of fatty acid binding protein (FABP)
WO2011053688A1 (en) 2009-10-29 2011-05-05 Schering Corporation Bridged bicyclic piperidine derivatives and methods of use thereof
WO2011062889A1 (en) 2009-11-23 2011-05-26 Schering Corporation Pyrimidine ether derivatives and methods of use thereof
US20120232073A1 (en) 2009-11-23 2012-09-13 Santhosh Francis Neelamkavil Fused bicyclic pyrimidine derivatives and methods of use thereof
US9301929B2 (en) 2009-11-24 2016-04-05 Merck Sharp & Dohme Corp. Substituted biaryl derivatives and methods of use thereof
WO2011113060A2 (en) * 2010-03-12 2011-09-15 Trana Discovery, Inc. Antiviral compounds and methods of use thereof
WO2012027331A1 (en) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
AU2014235215A1 (en) 2013-03-15 2015-10-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
ITMI20130555A1 (it) * 2013-04-09 2014-10-10 Giuliani Spa Composizione farmaceutica o cosmetica per contrastare l¿invecchiamento della pelle attraverso un¿azione antiinfiammatoria
BR112015030326A2 (pt) 2013-06-05 2017-08-29 Synergy Pharmaceuticals Inc Agonistas ultrapuros de guanilato ciclase c, método de fabricar e usar os mesmos

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1768934A1 (de) * 1968-07-15 1972-03-16 Bayer Ag Verfahren zur Anreicherung von Polypeptiden,vorzugsweise von Enzymen und Enzym-Inhibitoren
US4228274A (en) * 1976-09-28 1980-10-14 Merck & Co., Inc. 1-Substituted glycopyranosides
DE3123520A1 (de) * 1981-06-13 1982-12-30 Bayer Ag, 5090 Leverkusen Gesaettigte aminocyclitderivate, ihre herstellung undsie enthaltende arzneimittel
US5141739A (en) * 1986-07-03 1992-08-25 Advanced Magnetics, Inc. Delivery of x-ray contrast agents using receptor mediated endocytosis
AU3203489A (en) * 1988-02-19 1989-09-22 Upjohn Company, The Lipophilic polyamines useful for treating hypercholesterolemia
ATE83658T1 (de) * 1988-11-25 1993-01-15 Lubec Gert Behandlung von durch glucose ausgeloester quervernetzung von collagen bei diabetes mellitus-patienten durch arginin, spermidin, kreatin oder agmatin.
US5077313A (en) * 1988-11-25 1991-12-31 Gert Lubec Process for inhibiting pathological collagen cross-linking in diabetes patients
DD298412A5 (de) * 1989-04-28 1992-02-20 ������@���Kk�� Verfahren zur herstellung von polypeptiden, die geeignet sind als antagonisten exzitatorischer aminosaeure-neurotransmitter und/oder blocker der calciumkanaele
AU5739494A (en) * 1992-12-03 1994-06-22 Aristidis S. Charonis Protective role of polyamines in modifications of basement membrane macromolecules
US5744453A (en) * 1996-01-05 1998-04-28 Mintz; Clifford S. Polyamine conjugates for treatment of infection
NL1004379C2 (nl) * 1996-10-29 1998-05-08 Borculo Cooep Weiprod Toepassing van suikeraminen en suikeramiden als lijm, alsmede nieuwe suikeraminen en suikeramiden.
US7087648B1 (en) * 1997-10-27 2006-08-08 The Regents Of The University Of California Methods for modulating macrophage proliferation using polyamine analogs

Also Published As

Publication number Publication date
WO2001047528A2 (fr) 2001-07-05
FR2802817B1 (fr) 2002-10-11
EP1239863A2 (fr) 2002-09-18
US20030143713A1 (en) 2003-07-31
FR2802817A1 (fr) 2001-06-29
AU2687301A (en) 2001-07-09
CA2395305A1 (fr) 2001-07-05
WO2001047528A3 (fr) 2002-06-20

Similar Documents

Publication Publication Date Title
JP2003518501A (ja) 新規なグリコシダーゼ阻害剤および特に糖尿病を治療するためのその薬理学的使用
US12552743B2 (en) Oligonucleotide compositions and methods of use thereof
Lee Multiplicity of Ca2+ messengers and Ca2+ stores: a perspective from cyclic ADP-ribose and NAADP
US6617442B1 (en) Human Rnase H1 and oligonucleotide compositions thereof
AU2011208625C1 (en) Growth hormones with prolonged in-vivo efficacy
US5863903A (en) Use of hydroxy alkyl piperidine and pyrrolidine compounds to treat diabetes
EP0749423B1 (en) Piperidines and pyrrolidines
AU2005205867A1 (en) Transglutaminase mediated conjugation of peptides
Yang et al. Development of high-affinity ligands and photoaffinity labels for the D-fructose transporter GLUT5
US20100009397A1 (en) Substrate-mimetic akt inhibitor
US5432261A (en) Motlin-like polypeptide and use thereof
US5712258A (en) Inotropic ADP and ATP analogues and their pharmaceutical compositions
EP0824349A1 (en) Inhibitors of bacterial sialidase and methods of making and using the same
EP1850878A2 (en) C-terminally pegylated growth hormones
Hamel et al. Effects of cocaine on rat pancreatic enzyme secretion and protein synthesis
WO1993012084A1 (en) Aromatic peptidomimetics
CN120818044B (zh) 牦牛皮低聚肽及其制备方法和应用、功能性食品或药品
JPH11501043A (ja) Ｎｏシンターゼの阻害剤として活性を有するアルギニン類縁体
CN117430614B (zh) 一种异喹啉类衍生物及其合成方法和应用
CN118561859B (zh) 一类具有α-葡萄糖苷酶抑制活性化合物及其应用
CN120590476A (zh) 一种有助于降血糖的七肽及其应用
CN110922368B (zh) 一种氯代苯异噁唑氨基苯甲酸衍生物及其制备方法与应用
CN121574190A (zh) 一种具有降血糖作用的桑叶肽及其制备和应用
WO2002044218A1 (fr) Compose de derive d'acide hydroxamique et d'acide hyaluronique
CN121736051A (zh) 一种具有降血糖作用的六肽及其制备和应用

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20040721

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20040721

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080617

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20081118